GlassScriptPhysician profile
Derek Joseph Naccari
NPI 1871980128
$6,923.28
in general payments reported to CMS, 2019-2025
38 companies · $1,588 in 2025
The $1,588 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $203 · 2020: $240 · 2021: $172 · 2022: $745 · 2023: $1,963 · 2024: $2,013 · 2025: $1,588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,478 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,478.21 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,348.57 | 2020-2025 | |
| Lilly USA, LLC | $717.38 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $658.96 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $542.12 | 2022-2025 | |
| Novo Nordisk INC | $428.89 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $416.41 | 2019-2025 | Jardiance, Ofev |
| Amgen INC. | $405.69 | 2020-2025 | Otezla, Repatha, Evenity |
| Glaxosmithkline, LLC. | $348.60 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Exact Sciences Corporation | $243.90 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $195.15 | 2020-2025 | Capvaxive, Gardasil 9, Vaxneuvance |
| Janssen Pharmaceuticals, INC | $161.09 | 2019-2024 | Xarelto |
| Abbvie INC. | $160.08 | 2024-2025 | |
| Abbott Laboratories | $154.89 | 2021-2025 | Freestyle Libre |
| Astellas Pharma US INC | $132.01 | 2020-2023 | Veozah, Myrbetriq |
| Dexcom, INC. | $115.13 | 2024-2025 | Dexcom G6 Transmitter |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Naccari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.